Today’s Research Reports on Acerus Pharmaceuticals, Aptose Biosciences, ImmunoVaccine and Neovasc

NEW YORK, NY / ACCESSWIRE / February 27, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.

RDI has Initiated Coverage Today on:

Acerus Pharmaceuticals Corp.
https://rdinvesting.com/news/?ticker=ASP.TO

Aptose Biosciences Inc.
https://rdinvesting.com/news/?ticker=APS.TO

ImmunoVaccine Inc.
https://rdinvesting.com/news/?ticker=IMV.TO

Neovasc Inc.
https://rdinvesting.com/news/?ticker=NVCN.TO

Acerus Pharmaceuticals’ stock moved 3.70% higher Monday, to close the day at $0.28. The stock recorded a trading volume of 263,282 shares, which was below its three months average volume of 612,419 shares. In the last year, Acerus Pharmaceuticals’ shares have traded in a range of 0.10 – 9.80. The share price has gained 180.00% from its 52 week low. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $0.29 is greater than its 200-day moving average of $0.21. Shares of Acerus Pharmaceuticals have fallen approximately 3.45 percent year-to-date.

Access RDI’s Acerus Pharmaceuticals Corp. Research Report at:
https://rdinvesting.com/news/?ticker=ASP.TO

On Monday, shares of Aptose Biosciences recorded a trading volume of 31,964 shares, which was below the three months average volume of 62,768 shares. The stock ended the day 2.35% higher at 3.48. The share price has gained 231.43% from its 52-week low with a 52-week trading range of 1.05 – 4.80. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $3.53 is greater than its 200-day moving average of $2.45. Shares of Aptose Biosciences have gained approximately 25.18 percent year-to-date.

Access RDI’s Aptose Biosciences Inc. Research Report at:
https://rdinvesting.com/news/?ticker=APS.TO

ImmunoVaccine’s stock moved 3.06% lower Monday, to close the day at $1.90. The stock recorded a trading volume of 97,280 shares, which was below its three months average volume of 173,459 shares. In the last year, ImmunoVaccine’s shares have traded in a range of 1.00 – 2.55. The share price has gained 90.00% from its 52 week low. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $2.06 is greater than its 200-day moving average of $1.64. Shares of ImmunoVaccine have fallen approximately 19.15 percent year-to-date.

Access RDI’s ImmunoVaccine Inc. Research Report at:
https://rdinvesting.com/news/?ticker=IMV.TO

On Monday, shares of Neovasc recorded a trading volume of 611,711 shares, which was above the three months average volume of 219,109 shares. The stock ended the day 6.90% lower at 0.27. The stock is currently trading 90.43% below its 52-week high with a 52-week trading range of 0.26 – 2.82. The company’s shares are currently trading below their 200-day moving average. The stock’s 50-day moving average of $0.58 is below its 200-day moving average of $1.19. Shares of Neovasc are trading at a Price to Earnings ratio of 1.07. Shares of Neovasc have fallen approximately 64 percent year-to-date.

Access RDI’s Neovasc Inc. Research Report at:
https://rdinvesting.com/news/?ticker=NVCN.TO

Our Actionable Research on Acerus Pharmaceuticals Corp. (TSX:ASP.TO), Aptose Biosciences Inc. (TSX:APS.TO), ImmunoVaccine Inc. (TSX:IMV.TO) and Neovasc Inc. (TSX:NVCN.TO) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 490858